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Early in 2013, theWorld Health Organization (WHO) released a 2012 update to the 2002 State of the Science
of Endocrine Disrupting Chemicals. Several signiﬁcant concerns have been identiﬁed that raise questions
about conclusions reached in this report regarding endocrine disruption. First, the report is not a state-
of-the-science review and does not follow the 2002 WHO recommended weight-of-evidence approach.
Second, endocrine disruption is often presumed to occur based on exposure or a potential mechanism
despite a lack of evidence to show that chemicals are causally established as endocrine disruptors. Addi-
tionally, causation is often inferred by the presentation of a series of unrelated facts, which collectively
donot demonstrate causation. Third, trends indisease incidenceorprevalence arediscussedwithout regard
to known causes or risk factors; endocrine disruption is implicated as the reason for such trends in the
absence of evidence. Fourth, dose and potency are ignored formost chemicals discussed. Finally, controver-
sial topics (i.e., low dose effects, non-monotonic dose response) are presented in a one-sided manner and
these topics are important tounderstanding endocrinedisruption. Overall, the 2012 report doesnotprovide
a balanced perspective, nor does it accurately reﬂect the state of the science on endocrine disruption.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
In 2002, the World Health Organization (WHO), in collaboration
with the International Programme on Chemical Safety (IPCS), pro-
duced the Global Assessment of the State-of-the-Science of Endocrine
Disruptors (WHO-IPCS, 2002). In the intervening ten years, interest
in the question of endocrine disruption as a possible environmen-
tal issue has only increased and a substantial quantity of research
related to endocrine disruption has been conducted. Consequently,
a more current state-of-the-science review was warranted and the
WHO, in collaboration with the United Nations Environment
Programme (UNEP), published what is presented as an ‘‘update’’
to the 2002 report: State of the Science of Endocrine Disrupting
Chemicals – 2012 (WHO-UNEP, 2012a) and a companion report:
State of the Science of Endocrine Disrupting Chemicals 2012 Summary
for Decision-Makers (WHO-UNEP, 2012b).
The WHO-IPCS 2002 report was not an assessment of particular
agents or risks, but set out to summarize the prevailing state of
scientiﬁc knowledge – what was known, what was uncertain,
and what the prospects were for resolving the uncertainties with
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tion. The report described patterns in natural human and animal
populations that were considered possible manifestations of endo-
crine disruption and assessed the basis for evaluating whether
these patterns should be regarded as real and robust, whether
explanations for them other than endocrine disruption could be
possible, and what might be the state of toxicological evidence
for attributing them to an interference with endocrine-mediated
control by environmental chemicals at prevailing environmental
concentrations. Issues under debate were described forthrightly
along with the nature and extent of evidence available to support
the differing points of view. Importantly, the assessment was nota-
ble not only for its product, but also its process. A large and widely
representative set of international experts, including those with a
variety of views, articulated and employed a weight-of-evidence
methodology to integrate various kinds and lines of evidence and
to gauge how, and how well, the collective evidence supported
conclusions, which were then extensively reviewed. The aim was
to be appropriately circumspect, yet earnestly probing – that is,
neither to be alarmist, focusing only on feared possibilities, nor
to be complacent and dismissive of concerns that had yet to be
adequately supported scientiﬁcally. The WHO-IPCS 2002 assess-
ment largely succeeded in these aims and it won wide acceptance
and respect as an objective picture of what science had to say (and
the limits as to what current knowledge allowed it to say) about
the possibilities, prevalence, and magnitude of impacts of environ-
mental chemicals on natural populations through interaction with
endocrine systems.
Unfortunately, the 2012 report falls well short of the standard
set by the earlier 2002 assessment, both in its openness and objec-
tiveness of process and as a substantial evaluation of current scien-
tiﬁc knowledge and thinking on the issues. Whereas the 2002
assessment was produced by consensus among a large set of scien-
tists spanning the range of views on the matter, the 2012 report
was produced by a more limited set of authors. The 2002 report
articulated and used a weight-of-evidence evaluation process
and, while the 2012 report criticizes that process, it does not re-
place it with anything else, relying instead on an unexplained ‘‘best
professional judgment.’’ The 2002 report attempted to integrate
information on exposure, toxicological testing (including dose-
dependence of effects), the ability of putative disruptors to inter-
fere with endocrine-mediated control, and patterns of appearance
of possibly endocrine-related effects in populations. In contrast,
the 2012 report discusses each of these elements independently
and speciﬁcally declines to consider how these aspects can be
brought together to assess whether there are real and current
endocrine disruption problems or how well an integrated view of
the scientiﬁc evidence can answer that question.
The present paper identiﬁes several concerns regarding the
WHO-UNEP 2012 report. Namely, the report fails to present an
objective assessment of the current state of the science of endo-
crine disruption and does not, in fact, serve to update the 2002
assessment. Instead, the 2012 report seeks to replace the earlier
assessment with a much less thoroughly reasoned evaluation that
stresses possibilities of concern rather than an assessment of evi-
dence about whether those possibilities result in real human
health or environmental problems. An underlying concern with
the report is the presentation of evidence in a manner that infers
that the information demonstrates endocrine disruption without
full consideration of alternative explanations for the observed ef-
fects. This is partially achieved by the imprecise use of key terms
or concepts. For example, throughout the report there are sections
titled ‘‘Epidemiological evidence for EDCs [endocrine disrupting
chemicals] causing [insert health effect under discussion, e.g., early
puberty].’’ This title gives the reader an impression that evidence
will be presented on chemicals that cause that particular effect,when these sections should have more appropriately been charac-
terized as a discussion of EDCs associated with these effects. Sec-
tion 2.4 provides other examples and more detail on the use of
inference to imply rather than show that EDCs are causally associ-
ated with certain effects. The following Table 1 provides a sum-
mary of key terms, with their deﬁnitions, as used in this paper.
The observations, comments and criticisms of the WHO-UNEP
2012 report are provided with further discussion and examples be-
low. The aim of this critique is not to reevaluate these points, nor to
conduct a comprehensive assessment of the issue of endocrine dis-
ruption or the 2012 report. Rather this critique illustrates, with
speciﬁc examples, where the 2012 report has made statements
that claim or imply a ﬁnding about endocrine disruption as a cause
of actual effects, but have not been supported by a balanced and
thorough evaluation of the pertinent evidence. New data and
new understanding of the endocrine activity of chemicals have
been developed since 2002 and using this information to build
on the 2002 analysis is worthwhile – but, the WHO-UNEP 2012 re-
port does not achieve this goal. This paper focuses on the limita-
tions of the WHO-UNEP 2012 report and outlines speciﬁc
concerns that include: the inconsistency between the Summary
for Decision-Makers and the main report; the lack of a transparent
and systematic framework for identifying, reviewing, and evaluat-
ing data; the failure to update the 2002WHO-IPCS report as stated;
the informal approach to assessing causation from endocrine dis-
rupting chemicals (EDCs); the reliance on disease trends to suggest
associations with EDCs; and ignoring the role of exposure, dose,
and potency in endocrine disruption. Each of these key concerns
is presented below in the Discussion section and includes speciﬁc
examples of limitations in the WHO-UNEP 2012 report.2. Discussion
2.1. Companion report: summary for decision-makers
In addition to the State of the Science of Endocrine Disrupting
Chemicals – 2012 main report, a second publication, State of the
Science of Endocrine Disrupting Chemicals 2012 Summary for Deci-
sion-Makers was simultaneously released (WHO-UNEP, 2012b).
The relationship between the 2012 main report and the Summary
for Decision-Makers is confusing at best. Based on the title of this
document, one might presume that this document is a summary
of – or at least based on the analysis of – the main report. But a clo-
ser look reveals that the Summary is actually characterized as ‘‘an-
other product’’ of the process. In some cases, the Summary does
present an overview of key ﬁndings from the main report, but
there are many parts of the Summary which include conclusions
and assertions not reﬂected in the main report. Indeed, some con-
clusions are matters not mentioned at all in the main report. It is
very important to draw this distinction and make clear that the
Summary for Decision-Makers is not truly representative of the
content of the main report. Thus, there are even more shortcom-
ings in the Summary for Decision-Makers than in the 2012 report
itself.
The Summary for Decision-Makers presents a broader scope in
discussions and the statements are presented as more deﬁnitive
conclusions compared to those in the main report. For example, a
list of diseases are presented in Figure 5 of the Summary and de-
scribed as being induced by endocrine disrupting chemicals
(EDCs); however, no references are provided in the Summary to
support these inferences and insufﬁcient data are presented in
the main report itself to show that these diseases are in fact in-
duced or caused by any EDC. The lack of references in the Summary
or even cross-references to particular sections in the main report
makes it difﬁcult for any reader to ﬁnd the basis for many of these
Table 1
Key terms and deﬁnitions.
Key terms Deﬁnition
Endocrine disruptor ‘‘An endocrine disruptor is an exogenous substance or mixture that alters function(s) of the endocrine system and consequently causes
adverse health effects in an intact organism, or its progeny, or (sub) populations’’ (WHO-IPCS, 2002)
Adverse effect ‘‘Change in morphology, physiology, growth, development, reproduction or life span of an organism, system, or (sub) population that results
in an impairment of functional capacity, an impairment of the capacity to compensate for additional stress, or an increase in susceptibility to
other inﬂuence.’’ (IPCS, 2004)
Association Statistical relationship between two or more events, characteristics, or other variables
Causation To say that an agent causes an adverse effect means that the agent interacts with an organism to produce changes that lead to adverse effects
that would not have occurred had the agent not been present
Bradford Hill (1965) suggested several factors be considered to differentiate a causal association from a non-causal association. Based on a
modiﬁcation of the Bradford Hill criteria, WHO-IPCS (2002) developed causation criteria in a ‘‘structured format for assessing postulated
relationships between altered health outcomes and exposure to EDCs [endocrine disrupting chemicals].’’
Non-monotonic dose
response
‘‘non-[m]onotonic . . . dose response curves are often referred to as U-shaped (with maximal responses observed at low and high doses) or
inverted U-shaped (with maximal responses observed at intermediate doses).’’ (WHO-UNEP, 2012a,b, p. 8)
‘‘non-[m]onotonic dose responses (NMDRs) – measured biological effects with dose response curves that contain a point of inﬂection where
the slope of the curve changes sign at one or more points within the tested range.’’ (USEPA, 2013)
Threshold Dose or exposure concentration of an agent below which a stated effect is not observed or expected to occur (USEPA, 2014; IPCS, 2004)
Potency The power of an agent to produce a desired effect (Dorlands Medical Dictionary)
Together, afﬁnity and efﬁcacy determine the potency of a ligand [an agent] to activate speciﬁc hormone receptors and to elicit speciﬁc cellular
responses in target tissues (Borgert et al., 2013)
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Efforts to simplify the information for decision makers or lay peo-
ple have resulted in a failure to appropriately characterize or pres-
ent the existing data gaps and uncertainties. Consequently, the
Summary overstated the strength of its conclusions. For example,
the Summary stated that EDC exposures are linked with a variety
of neurobehavioral diseases or disorders, of which dyslexia is in-
cluded, but in the main report, the only data provided on dyslexia
relate to trends in prevalence and no information is given on an
association, let alone causation, with any EDC. Additionally, the
Summary approached the state of the science from the same per-
spective as the main report, and consequently, has many of the
same limitations related to: the lack of a framework for evaluating
data and conducting a weight of evidence review, the use of infer-
ence to imply causal relationships between chemicals and diseases,
the reliance on disease trends to suggest associations with EDCs,
and ignoring the role of dose and potency in endocrine disruption.
2.2. State of the science?
How the WHO-UNEP 2012 report is to be considered an assess-
ment of the state of the science is unclear to the reader. The report
never deﬁnes what might be meant by ‘‘state of the science’’ nor
discusses what such an assessment should cover and characterize.
A state-of-the-science review should have a deﬁned scope with a
systematic approach to the collection and review of data, and a
clear methodology for the integration and assessment of these
data. Several factors need to be considered in the process of inte-
grating and interpreting data, particularly when evaluating the rel-
evance of experimental animal studies to human health or wildlife.
To that end, one of the key concerns is how dose–responses ob-
served in experimental animal studies compare to the exposures
potentially experienced by humans or wildlife. Other factors that
also should be considered in the integration of data include: the
quality of the available data, the consistency of the results, the
presence of bias and confounding factors that may inﬂuence the
ﬁndings, and the identiﬁcation of data gaps. When interpreting
data, the complete spectrum of ﬁndings should be considered
and any controversy or debate on the issues at hand should be pre-
sented. As discussed in greater detail below, given the undeﬁned
scope and lack of a structured methodology for integrating andassessing the weight of evidence in the WHO-UNEP 2012 report,
the state of the science was not evaluated in a consistent, objective
manner. In some cases, the weaknesses of the data are acknowl-
edged, such as the lack of data on EDC exposure and ovarian can-
cer; in other cases, important studies are ignored that counter
those cited in the report.
The literature published on the potential endocrine activity of
speciﬁc chemicals is extensive and beyond the scope of either
the 2002 or 2012 reports. Neither report could be expected to
undertake complete reviews for even a small subset of chemicals,
but a systematic methodology would have ensured that a repre-
sentative spectrum of the available literature was captured in the
review. Publications selected for discussion in the report were
not systematically assessed for their quality; nor were the results
placed in a broader perspective. The only description of the litera-
ture retrieval process indicates that emphasis was placed on liter-
ature published after 2000 through March 2012. Despite the
claimed focus on literature available in the last ten years or so, a
substantial number of citations relied upon in the 2012 report
are ones that were previously cited in the 2002 report or were pub-
lished prior to the turn of the century. The conclusion that the
WHO-UNEP 2012 report is not an actual update to WHO-IPCS
2002 report, but rather, a reworking of that earlier report is further
supported by the 2012 report’s strong reliance on older citations.
This is discussed more fully in Section 2.3 of this paper.
A particular concern regarding the data collection process is that
there seems to be a strong preference toward citing studies that re-
port an association with exposure and omitting those studies that
do not support such associations. For example, studies that showed
some association between levels of pesticides in the environment
and adverse effects on frogs are cited (e.g., Hayes et al., 2003;
McDaniel et al., 2008), while studies to the contrary (e.g., Du Preez
et al., 2009; Kloas et al., 2009; Murphy et al., 2006; Skelly et al.,
2010; Smith et al., 2005; Spolyarich et al., 2011) are not mentioned.
The same is true of the experimental studies cited for thyroid effects
from polychlorinated biphenyls (PCBs). While twelve studies were
cited in the discussion, half of these studies were from one research
laboratory and thus do not represent independent veriﬁcation of
ﬁndings in separate laboratories. Other studies investigating PCB
effects on the thyroid were not included in the review (e.g., Kato
et al., 2004, 2010; Martin and Klaassen, 2010). Another example
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to cite many of the experimental animal studies on bisphenol A
(BPA) that were conducted with larger numbers of animals and
dose groups under Good Laboratory Practices (GLP) (e.g., Stump
et al., 2010; Tyl et al., 2002, 2008). As recommended by Conrad
and Becker (2011a,b), all well conducted laboratory studies, both
GLP and non-GLP, should be considered in a review in order to pro-
vide a comprehensive understanding of the mode of action (MOA),
hazards, and risks of a chemical. It is not expected that all of the
available data could be critically reviewed in the state-of-the-sci-
ence report, but greater objectivity and balance would have helped
the reader better understand the controversies and elucidate the
key uncertainties that exist in the ﬁeld of endocrine disruption.
A discussion of divergent results in the literature is essential to
determine why different results were generated, particularly since
one of the hallmarks of science is reproducibility. If only one of sev-
eral laboratories is able to generate a particular outcome, it sug-
gests that the outcome is not very robust or that there may be
something unique in how the results were obtained and thus they
may not be reliable. An additional reason for discussing divergent
results is to make the reader aware of controversy that is funda-
mental to the scientiﬁc process, rather than give a false sense of
agreement. Only an informed individual can make decisions about
the impact of data discrepancies in the use of these data. Finally, by
identifying studies with divergent ﬁndings, important gaps in
understanding are characterized and potential research priorities
can be better formulated. Thus, the failure to identify studies with
different results is potentially misleading, contrary to best scien-
tiﬁc practices, and does not facilitate sound policy decisions.
An additional concern regarding the speciﬁc citations refer-
enced in theWHO-UNEP 2012 report are the discrepancies that ex-
ist between the ﬁndings reported in the publications and how
these ﬁndings are described in the WHO-UNEP report. For exam-
ple, it is stated in the WHO-UNEP report that ‘‘[a]rsenic exposure
is strongly associated with prostate cancer’’ and two citations are
provided (Benbrahim-Tallaa and Waalkes, 2008; Schuhmacher-
Wolz et al., 2009 in WHO-UNEP, 2012a, p. 131). One of these cita-
tions, Schuhmacher-Wolz et al. (2009), merely references the
other. The statement in the WHO-UNEP 2012 report does not re-
ﬂect the outstanding questions about potential prostate cancer risk
at low environmental exposures. The association between arsenic
in drinking water and prostate cancer is primarily based on the re-
sults of ecological studies in Taiwan, which are not sufﬁcient for
assessing causation. The potential MOA is not deﬁned and is only
speculated to be endocrine-mediated. Furthermore, the Interna-
tional Agency for Research on Cancer (IARC, 2004), which reviewed
the same epidemiology studies as Benbrahim-Tallaa and Waalkes
(2008), concluded that there was sufﬁcient evidence for arsenic
in drinking water to cause skin cancer, lung cancer, and bladder
cancer, but no conclusions were reached based on prostate cancer.
Thus, the statement in the WHO-UNEP 2012 report that arsenic is
‘‘strongly associated with prostate cancer’’ is not consistent with
IARC’s more comprehensive review of the same literature.
Later in the discussion of mechanisms for prostate cancer, Soto
et al. (1995) is cited as ‘‘good evidence that the organochlorine pes-
ticides [are] shown to be associated with increased prostate cancer
risks.’’ In fact, the publication of Soto et al. (1995) relates to an
in vitro assay and does not deal with the risk of prostate cancer from
pesticides. Similarly, Yolton et al. (2011) is cited as showing that
concentrations of BPA and phthalates inmaternal urine during early
pregnancy were associated with higher hyperactivity and aggres-
sion in 2-year old girls, but not in boys (WHO-UNEP, 2012a, pp.
114–115). This appears to be in error since the reference cited did
not investigate hyperactivity or aggression. However, an earlier
publication from the same research group, Braun et al. (2009),
reported an association between mean urinary BPA concentrationsand behavior scores in female children – but no assessment of
phthalates was conducted in this earlier study. Finally, Figure 2.31
(WHO-UNEP, 2012a, p. 182) presents data on concentrations of
DDE (dichlorodiphenyldichloroethylene, ametabolite of dichlorodi-
phenyltrichloroethane [DDT]) in osprey eggs, with a straight line
drawn through the points to depict a clear decline over time. This
ﬁgure is reported to be ‘‘based on data from Henny et al. (2010).’’
The original paper, however, does not draw a best-ﬁt line through
these values, but rather, the data are presented in a bar graph with
no statistically signiﬁcant differences for the time periods: 1981–
82, 1993, 1998, and 2000–01. In other words, there is no real trend
for these four periods; only the values in 2006 and 2008 show a sta-
tistically signiﬁcant decrease in DDE concentrations in osprey eggs.
These are just a few examples of the discrepancies found in the
WHO-UNEP 2012 report; they do not reﬂect all of the citations that
have been mischaracterized or mistakenly referenced. In some
cases, the discrepancies may only be mistakes in referencing the
correct citation, but in others, there appears to be a tendency to
exaggerate the ﬁndings or conclusions of the original authors.
Finally, a process for assessing the quality or reliability of the
studies considered for review in the WHO-UNEP 2012 report is
not described. In fact, the quality of the underlying studies does
not appear to have been evaluated at all. This is of particular con-
cern because not all studies should be given the same weight. For
example, epidemiology studies that employ weak research designs
(e.g., ecological and cross-sectional study designs) or include small
sample sizes should not be given as much weight as studies with
stronger designs (e.g., case-control and cohort studies) and larger
sample sizes. Also, comparing in vitro exposures to relevant
in vivo exposures is fraught with difﬁculties. In vitro studies can
be relevant for investigating MOA and potential for endocrine
activity, but cannot provide useful information on dose–response,
do not take into account the disposition of a chemical in the body
(its absorption, distribution, metabolism and elimination), and fail
to account for homeostasis or other pathways and processes that
respond to certain MOAs. Various methods exist to evaluate and
weigh the quality and reliability of studies included in a review,
such as the systematic approach for evaluating toxicology and eco-
toxicology data described by Klimisch et al. (1997), which is also
employed by the Organization for Economic Cooperation and
Development (OECD) and relied upon by the OECD’s 34 member
countries in the investigation of high production volume chemicals
(OECD, 2005). Yet inexplicably, neither this approach nor an alter-
native approach for evaluating the quality of the data reviewed
was applied in the WHO-UNEP 2012 review.
Most importantly, the WHO-UNEP 2012 report did not adopt a
weight-of-evidence approach for the evaluation of data on endo-
crine disruption. In the 2002 review, an objective and transparent
framework was developed for assessing the relationship between
potential EDCs and health outcomes, which the 2012 report does
not apply in its evaluation and interpretation of data. Further, no
alternative approach was proposed or applied to evaluate the
weight of evidence. However, an overall evaluation of the data
must have been conducted because conclusions at the end of each
section discussing health effects are titled: Strength of Evidence. No
description is provided regarding how this ‘‘strength of evidence’’
was determined, although ‘‘best professional judgment’’ (WHO-
UNEP, 2012a, p. 19) was said to be applied. Speciﬁc concerns about
the lack of a structured approach for assessing causation in the
2012 report are further discussed in Section 2.4 of this paper.
In the WHO-UNEP 2012 report, evidence for endocrine disrup-
tion in humans and wildlife is presented as narrative reviews of
the data. These assessments were described as being founded on
an aggregation of the information related to biological plausibility,
relevant exposures, consistency of the data across species, and
dose–response and temporality (WHO-UNEP, 2012a, p. 19).
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tion of the data. For example, biological plausibility is often cited
in the 2012 report as the basis of concern for causality, but the evi-
dence presented generally is limited to data on the role of endog-
enous hormones and not based on mechanistic data, potency or
actual exposures for any of the chemicals of potential concern.
Exposure data are clearly not integrated with the rest of the data,
as exposure information is provided separately in Chapter 3 of
the WHO-UNEP 2012 report. Species concordance is frequently
used to try and bridge experimental animal or wildlife data with
human data on particular observed effects, but there is a lack of
integration of the data with exposure information or mechanisms.
Potential species differences do not seem to have been considered,
and in some cases, these differences may be critical to the interpre-
tation of the data (an example is provided regarding thyroid effects
in Section 2.6.2). Although the report purports to incorporate dose–
response in its evaluation of the evidence, it tends to be ignored
when speciﬁc chemicals or adverse outcomes1 are discussed; this
issue is discussed in greater detail in Section 2.6 below.
Other factors not speciﬁcallymentioned in theWHO-UNEP 2012
report that should have been considered in the integration and
interpretation of data include the reproducibility of the data and
consistency of data across different lines of evidence (epidemiology,
in vivo and in vitro data), data gaps, and the existence of controversy
or differences in interpretation of study ﬁndings. Asmentioned pre-
viously, the reproducibility of a ﬁnding in different studies, differ-
ent research labs, or in different study populations was not
addressed in the report. Although it is noted in a number of places
where signiﬁcant gaps still exist in the data, these data gaps and
their implications are not always carried forward into the report
conclusions. Further, no speciﬁc research recommendations are
provided based on such data gaps in the 2012 report, which is an
important and useful element for developing data in the future.
Other recently published reports have done a better job of pro-
viding state-of-the-science reviews on controversial issues in sci-
ence. For example, the U.S. Environmental Protection Agency
(USEPA) recently released a draft review on the scientiﬁc issues sur-
rounding the phenomenon of a non-monotonic dose–response
(NMDR) (USEPA, 2013). USEPA took a methodical and even-handed
approach to its review. The scope of the report was provided, clearly
stating the scientiﬁc questions that were to be addressed. USEPA
also clearly described and respected the limits of the report; for
example, they acknowledged that it was not a comprehensive trea-
tise. In a succinctmanner, USEPA described both the supporting and
conﬂicting evidence for NMDRs. As part of this assessment, the
uncertainties associated with the interpretation of the data were
considered. Overall, the USEPA draft report on NMDRs is a good
example of a well-conducted, state-of-the-science review and illus-
trates how controversial issues, such as NMDRs, can be approached
in an objectivemanner. Similarly, the European Food Safety Author-
ity (EFSA) reviewed a developmental neurotoxicity (DNT) study in
rats and other recent scientiﬁc literature in context of the risk
assessment for BPA (EFSA, 2010), a compound mentioned in the
WHO-UNEP 2012 report as being an EDC. Although EFSA’s review
had anarrowscope, speciﬁc parameterswere provided for the inclu-
sion of studies in the assessment. EFSA also described its reliance on
clear ‘‘quality criteria’’ to assess the strengths andweaknesses of the
studies it reviewed. Those criteria addressed issues of study design,
conduct, recordkeeping, and interpretation. The EFSA review pro-
vides an example in which a comprehensive evaluation of the liter-
ature considers explanations for toxicity beyond those related to
endocrine disruption; a feature which is not generally considered1 When referring to adverse outcomes in this paper, this includes adverse health
effects in humans, experimental animals, and wildlife.in the WHO-UNEP 2012 report. A ﬁnal example is the independent
reviewby theNational ResearchCouncil (NRC) on theadversehealth
effects associatedwith perchlorate ingestion (NRC, 2005) and USEP-
A’s draft risk assessment for perchlorate. The scope of the panel’s re-
view was outlined with speciﬁc issues to be addressed including
whether or not USEPA ‘‘considered all relevant literature (both sup-
porting and non-supporting), consistently critiqued that literature,
and thenusedappropriate scientiﬁc studies todevelop its health risk
assessment’’ (p. 30). Thus, the full spectrum of evidencewas consid-
ered in the NRC’s review and a systematic approach was used to
evaluate the data. The NRC report is a comprehensive, systematic
review utilizing a weight-of-evidence approach to investigate a
potential causal relationship and considered dose–response in
evaluating potential human health effects.
Overall, the WHO-UNEP 2012 report does not meet the expec-
tations of a state-of-the-science review. In contrast to the above
examples of state-of-the-science assessments conducted and
based on objective reviews of the literature, using sound method-
ology and deﬁned goals, the WHO-UNEP 2012 report did not pro-
vide a summary of the state of the science for endocrine disruption.
A number of limitations regarding the lack of a deﬁned scope for
the review, the absence of a process for identiﬁcation, integration,
and interpretation of data, and the lack of a structure for evaluating
the weight of the evidence calls into question the conclusions
reached in the report. The WHO-UNEP 2012 report can, at most,
be characterized as a discussion of some of the scientiﬁc issues that
should be considered when discussing endocrine disruption, but it
is not, by any means, a true summary of the state of the science.
2.3. Not an update of 2002 state-of-the-science report
Although the WHO-UNEP 2012 report is described as an update
of the WHO-IPCS 2002 Global Assessment of the State-of-the-Science
of Endocrine Disruptors (WHO-IPCS, 2002), it does not achieve this
goal. An update relies and builds upon the information reviewed
and assessments of data from an earlier document. TheWHO-UNEP
2012 report reviews much of the same information cited in the
2002 report by frequently citing literature from the year 2001 or
earlier. Although there is a section in each subchapter on speciﬁc
health effects that is titled Scientiﬁc progress since 2002, these are
only brief sketches that are not sufﬁciently scientiﬁcally robust to
achieve the objective of fully revisiting the state of scientiﬁc under-
standing. Often, the information contained therein is limited to a
series of bullets that lack citations in support of the statements
made. In some cases, the support for these bullets in the text of
the chapter is scant, and it generally does not reﬂect the scientiﬁc
consensus or weight of evidence available on the topic at hand.
Importantly, there is no consideration of whether new information
changed the state of understanding since the earlier 2002 report.
The WHO-UNEP 2012 report does not provide any follow-up on
the research recommendations presented in the WHO-IPCS 2002
report, nor are any new research recommendations presented.
Notably, there are no references to the conclusions reached in the
WHO-IPCS 2002 report; nor does the WHO-UNEP 2012 report pro-
vide any support or explanation when its conclusions differ from
the 2002 report. Thus, it is unclear in what way the WHO-UNEP
2012 report can be considered an ‘‘update.’’
Perhaps the most signiﬁcant factor that belies the characteriza-
tion of the WHO-UNEP 2012 report as an update is the failure to
use the framework and causal criteria for assessing endocrine dis-
ruptors originally proposed in the WHO-IPCS 2002 report. The
framework put forward in the WHO-IPCS 2002 report was based
on established and broadly accepted scientiﬁc methods for the
evaluation of data to determine whether associations could be con-
sidered causally related – not just chance ﬁndings or the result of
bias. Not only does the WHO-UNEP 2012 report not rely on the
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also does not provide an appropriate alternative framework by
which the data could be assessed to determine causal relation-
ships. Instead of using clear and objective principles as the founda-
tion for the report, ‘‘best professional judgment’’ was used (WHO-
UNEP, 2012a, p. 19) without fully describing any criteria by which
such judgment was to be applied. Consequently, the WHO-UNEP
2012 report is not an update but, rather, a selective re-evaluation
of information largely included in the 2002 report.
In order to better understand why and how the WHO-UNEP
2012 report is not an update of the WHO-IPCS 2002 report, se-
lected examples are provided below of adverse outcomes reviewed
in both documents. These examples compare the data relied upon,
how the available evidence was characterized, the state of the sci-
ence, and conclusions reached about the weight of evidence in the
respective reports.
2.3.1. Sperm/semen quality
Sperm or semen quality was evaluated in both state-of-the-sci-
ence reviews. The WHO-IPCS 2002 report concluded that a global
trend for declining semen quality was not supported by the existing
data. This conclusion was based on a broad review of studies investi-
gating spermcounts, fromtheﬁrst study suggesting adecline (Nelson
andBunge, 1974), and included theﬁrstmeta-analysis (Carlsen et al.,
1992), longitudinal retrospective studies in single centers (e.g.,
Auger et al., 1995), and broader investigations around the world
(e.g., Auger and Jouannet, 1997; Jørgensen et al., 2001; Swan et al.,
1997; Younglai et al., 1998). The review in the 2002 report described
the limitations and biases of the various studies. Concerns included
the use of retrospective study designs, evaluation of semenor sperm
samples frommen thatmaynothavebeen representativeof thegen-
eral population (e.g., patients at infertility clinics), differences in
methods for recruiting study subjects, variability in analyticalmeth-
ods, and lack of control or consideration of the other factors that are
known to impact sperm quality (e.g., age, sexual abstinence). The
lack of data on speciﬁc chemical exposures raised questions about
assessing the strength of the association. TheWHO-IPCS2002 report
acknowledged that, while it was biologically plausible and some
experimental evidence was available to support EDCs affecting
sperm quality, the ‘‘lack of any demonstration to date of an endo-
crine-disruptingmechanism for other chemical exposures indicates
the need for more studies before ﬁrm conclusions can be drawn’’
(WHO-IPCS, 2002, p. 56). In its evaluation of the strength of evidence
for: SemenQuality and Testis Function inHumans (WHO-IPCS, 2002, p.
124), the2002 report concluded that theoverall strengthof evidence
was weak based on an assessment of temporality, strength of asso-
ciation, consistency, and biological plausibility.
TheWHO-UNEP 2012 report described various studies of declin-
ing semen quality, also startingwith the ﬁrst meta-analysis by Carl-
sen et al. (1992) and cites many of the same references relied on in
the WHO-IPCS 2002 report. The discussion is not limited to or fo-
cused on the newest studies on sperm or semen quality, nor is it a
comprehensive review of all of the data. Although several prospec-
tive studies of the general populationwerementioned as being con-
ducted byNordic, Baltic, German, Spanish and Japanese researchers,
the only citations provided are two studies of Finnish and Danish
men (Jørgensen et al., 2011, 2012). A retrospective analysis of French
men with total infertile partners that were subjects in assisted
reproductive technology was also cited (Rolland et al., 2013). How-
ever, several other studies published since the WHO-IPCS 2002 re-
port that do not show a decrease or an increase in sperm counts
are not cited (e.g., Axelsson et al., 2011; Costello et al., 2002; Elia
et al., 2012;Marimuthu et al., 2003; Pal et al., 2006). In a recent com-
mentary from Bonde et al. (2011), it is shown that sperm cell counts
inDanishmilitarydrafteeshave remained stable and, in fact, suggest
higher counts in the last four years of the study between 2007 and2010. This contribution to the extensive and ongoing discussion
about spermcell count trends is not cited at all. The selective citation
of literature and the failure to includemany studies that do not sup-
port a decline in sperm counts indicates that the 2012 report pro-
vided an unbalanced review of the literature.
Unlike the WHO-IPCS, 2002 report, there is no mention of the
limitations and potential biases of any of the studies reviewed, de-
spite the fact that all of the limitations noted in the 2002 report
continue to apply. The new, prospective studies highlighted in
the 2012 report also have low study participation rates: 13.4% in
the Finnish study (Jørgensen et al., 2011) and 24% in the Danish
study (Jørgensen et al., 2012). Such low participation rates raise
concerns about whether the men in these studies were truly repre-
sentative of the general population. Furthermore, there is only a
brief mention that the issue of declining sperm counts remains
controversial. Questions about the implications of conﬂicting ﬁnd-
ings related to sperm quality are not carried over into the conclu-
sions on male reproductive health. Recent reviews of this issue
continue to characterize the reports of declining sperm counts as
controversial because of the differences seen geographically and
temporally (Fisch and Braun, 2013; Sharpe, 2010). These reviews
identify a number of factors that may account for these differences
that are not related to endocrine disruption, such as lab techniques,
sexual behavior resulting in differences in abstinence, lifestyle fac-
tors (e.g., obesity, drug use), and genetic variations.
The WHO-UNEP 2012 report presents limited data regarding
speciﬁc EDCs and the potential for affecting sperm quality. Epide-
miology studies are characterized as showing weak associations
with EDCs, which is based on single citations for most of the chem-
icals of possible concern identiﬁed in the report. Single publica-
tions are not sufﬁcient to assess the weight of evidence (or to
provide one’s ‘‘professional judgment’’) of a potential association
between an exposure and an adverse effect. Furthermore, the
2012 report does not evaluate the limitations of these studies;
nor does it consider experimental animal studies in conjunction
with epidemiology to assess the hypothesis that EDCs could cause
male reproductive disorders, including effects on sperm or semen
quality. The 2012 report relies only on ‘‘suboptimal or poor semen
quality in large proportions (20–40%) of men in countries in which
this has been studied’’ and that there is ‘‘some evidence for a
declining semen quality,’’ thereby suggesting that these perceived
trends are the consequence of exposure to endocrine disruptors
with no strong evidence to support this claim.
Despite acknowledging that the epidemiology data only show
weak associations for a decline in sperm quality related to speciﬁc
EDCs, the conclusions in the 2012 report for male reproductive
health focus on the observation of decreased sperm counts, ignor-
ing the variability in sperm quality reported around the world and
the well founded scientiﬁc questions that have been raised about
this issue. Based on the evidence presented in the WHO-UNEP
2012 report, it does not appear that the evidence for changes in
sperm quality differ from that reported in the WHO-IPCS 2002 re-
port. Therefore, the reason for the discrepancy between the conclu-
sions of the two reports is difﬁcult to explain. When an objective,
structured, and transparent weight-of-the-evidence analysis
reaches one conclusion and a subjective analysis concludes the
opposite, logic dictates the driving force for such a difference stems
from the methodology and bias inherent in a subjective analysis.
2.3.2. Adrenal disorders
As noted in the WHO-UNEP 2012 report, adrenal dysfunction
was not discussed in detail in the WHO-IPCS 2002 report because
the ‘‘available research to date [was] very limited’’ (WHO-IPCS,
2002, p. 86). The observation of severe adrenocortical hyperplasia
in the Baltic ringed and gray seal were mentioned and it was stated
in the 2002 report that although adrenal effects in wildlife were
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PCBs, the involvement of these compounds in the cause of these
disorders was uncertain.
The WHO-UNEP 2012 report contains a speciﬁc section discuss-
ing adrenal disorders, which seems appropriate given the lack of
systematic review in 2002. The information presented in the
WHO-UNEP 2012 report focuses heavily on data and literature from
2002 or earlier, particularly regarding effects in wildlife. This sug-
gests that the state of knowledge regarding endocrine disruption
related to perturbations of the adrenal gland has not changed sig-
niﬁcantly since 2002. No new data are provided on the observation
of adrenocortical hyperplasia in Baltic seals – the one new article,
Lind et al. (2003), addresses bone mineral density in Baltic grey
seals, not adrenocortical hyperplasia. Signiﬁcantly, there is a change
in the conclusions about the weight of evidence regarding adreno-
cortical hyperplasia in wildlife and various compounds, despite the
lack of new information. In 2002, this was considered an uncertain
association, but in 2012, it was concluded that this was a causal
relationship. This change in the interpretation of the data should
have been highlighted and the evidence to support this change
should have been stated explicitly. Additional concerns about the
weight of evidence regarding the causal relationship between expo-
sure to EDCs and the observation of adrenocortical hyperplasia in
Baltic seals are discussed later in this paper (see Section 2.4.1). It
is unclear how a more deﬁnitive conclusion could be reached
regarding adrenocortical hyperplasia based on essentially the same
data reviewed in 2002, which suggests that the WHO-UNEP 2012
report is not an update, but a re-interpretation, of the same data.
Alternatively, the authors of the WHO-UNEP 2012 report may view
the 2002 report as ﬂawed. If this is the case, then the reasons behind
the divergent opinions should have been explicitly stated.
2.3.3. Endometriosis
In the WHO-IPCS 2002 report, endometriosis was reviewed as a
reproductive outcome possibly associated with EDCs. Some epide-
miology studies of PCBs and dioxins indicating associations with
endometriosis were contrasted with other studies that failed to ob-
serve an association. Experimental animal evidence was presented
for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and the data were
judged to be conﬂicting – some studies indicated that TCDD may
have a role in the development of endometriosis, but other studies
did not support such an association. The 2002 report mentioned
the criticisms of the studies of TCDD in rhesus monkeys, including
factors potentially confounding the results. The question of rele-
vance of the rodent studies for humans was also raised given the
high doses required to induce endometriosis in rodents. Regarding
possible MOAs, the roles of estrogen and progesterone were dis-
cussed in the context of known disease development and the aryl
hydrocarbon receptor (AhR) was reviewed in relation to TCDD
exposure and endometriosis. The 2002 report concluded:
‘‘Relative to the hypothesis of an association between a stressor and an out-
come, evidence is judged to be weak because of conﬂicting data from humans
and animals, lack of association in women exposed to high amounts of TCDD,
and antiestrogenic effects of TCDD. In humans, occurrence of endometriosis
shows dependency on estrogen–progesterone balance, suggesting that an
EDC-related mechanism may be possible.’’ (WHO-IPCS, 2002, p. 125)
The WHO-UNEP 2012 discussion on endometriosis is not an
update of theWHO-IPCS 2002 report as it mainly consists of a re-re-
view of the information evaluated in 2002. A majority of the litera-
ture cited in the WHO-UNEP 2012 report linking TCDD to
endometriosis was cited in the WHO-IPCS 2002 report, but the
2012 report failed to note that many of these studies (e.g., Bruner-
Tran et al., 1999; Rier et al., 2001) employed high doses of TCDD,
which were considered of questionable relevance to endometriosis
in humans in the2002 report.Muchof the PCB literaturewas also re-
viewed and cited in the earlierWHO-IPCS 2002 report. Although theWHO-UNEP 2012 report cites nine publications as ﬁnding a ‘‘rela-
tionship between circulating phthalate (and phthalate esters) and
endometriosis’’ (p. 44), none of these publications mention phtha-
lates. Four other publications are mentioned regarding studies on
phthalate ester metabolites, but the ﬁndings are inconsistent for
various phthalate esters, which is acknowledged in theWHO-UNEP
2012 report. It is interesting to note that, in the discussion of phthal-
ate esters and endometriosis, there is no mention of a study by Itoh
et al. (2009) thatdidnotobserveanassociationbetweenmeasuresof
phthalate metabolites in urine and endometriosis. Regarding a po-
tential MOA for endometriosis, general hormonal inﬂuences on the
disease are discussed, but little information is reviewed on speciﬁc
EDCs. The WHO-UNEP 2012 report stated that epigenetic changes
have been reported to be involved in endometriosis – particularly
those induced by in utero exposure. However, only two review arti-
cles are cited (Cakmak and Taylor, 2010; Guo, 2009), neither of
which address causal relationships for speciﬁc chemicals. It is not
clear what, if anything, has changed regarding the state of the sci-
ence in terms of cause and effect for endocrine disruption and endo-
metriosis since the WHO-IPCS 2002 report.
The examples above illustrate how the WHO-UNEP 2012 report
is not an update of the WHO-IPCS 2002 report. In some cases, the
2012 report reaches conclusions that conﬂict with those reached in
the earlier report, despite the lack of new information to support a
change in the weight of evidence. In other cases, the 2012 report
simply presents a re-evaluation of the studies reviewed in 2002.
The fact that the 2012 report often reaches more deﬁnitive conclu-
sions based on the same data emphasizes the use of non-transpar-
ent, subjective decision making for evaluating potential causal
relationships compared to the earlier 2002 report. In light of this,
although the 2012 report is stated to be an update, in actuality,
the 2012 report is a revised review of the state of the science pre-
sented in 2002 and does not build upon what was previously done.
2.4. Inference, not causation
Causation is a critical element in thedeﬁnitionof anendocrinedis-
ruptor and consideration of causal relationships should have been gi-
venmore attention in theWHO-UNEP 2012 report. Instead, the 2012
report tended to focus on only part of the deﬁnition of an endocrine
disruptor – the potential to alter some aspect of endocrine function.
Consequently, information is presented or discussed on possible or
potential endocrine disruption without considering whether altera-
tions to the endocrine system caused any adverse effects. The failure
to differentiate between the potential for endocrine system interac-
tion of some sort and actual disruption of control of physiology or
development as a result of such interactions misleads the reader
about the weight of evidence for particular disruptive effects. This
could result in inappropriate regulatory actions and research priori-
ties when additional research still might be needed to establish these
causal relationships. Any state-of-the science review should be a bal-
anced and objective reviewof all of the available literaturewith iden-
tiﬁcation of data gaps along with clear statements of the conclusions
supported by the data and the inferences that cannot be supported.
Only through such an approach can all parties, in particular, stake-
holders without a strong scientiﬁc background, be conﬁdent in the
evidence-based decisions that arise from such a report.
There have been many deﬁnitions for an endocrine disruptor
over the years and the WHO-UNEP 2012 report stated it relies on
the deﬁnition in general use today; this same deﬁnition was used
in the WHO-IPCS 2002 report. Integral to this deﬁnition are three
important components:
 The substance must act through an endocrine MOA that alters
function of the endocrine system;
 The substance must cause an adverse health effect; and
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consequence of the altered endocrine function.
All three of these components are necessary to demonstrate
that a chemical is an endocrine disruptor. This requires the differ-
entiation between endocrine-mediated effects from other known
MOAs and the linking of an observation of an adverse effect to that
endocrine MOA. Various chemicals or classes of chemicals were
presented in the WHO-UNEP 2012 report as though they were
EDCs, but the report does not provide any information to show that
the effects of these chemicals are, in fact, the result of alterations in
endocrine function. In the 2012 report, the interference with endo-
crine function by a chemical is often considered sufﬁcient evidence
for endocrine disruption, when in fact this only demonstrates that
a chemical has the ability to interact with the endocrine system
(Tinwell et al., 2013) and the potential for endocrine disruption.
The WHO-UNEP 2012 report frequently relies solely on the
observation of adverse effects in endocrine organs or the existence
of possible endocrine MOAs. The report often reaches conclusions
based on only one or two elements of the deﬁnition for an endo-
crine disruptor. It is the third and essential component of the def-
inition that leads to the determination of endocrine disruption. In
order to reach the conclusion that a chemical is an endocrine dis-
ruptor, one needs to have a systematic method for assessing causa-
tion. Various methods have been developed to assess causal
relationships; the most commonly referenced approach relates to
the criteria outlined by Sir Austin Bradford Hill (Hill 1965). The
WHO-IPCS 2002 framework was proposed based on Bradford Hill’s
criteria to assess relationships between exposures to potential
EDCs and altered health outcomes (see WHO-IPCS, 2002, Chapter
7). Several factors were speciﬁcally considered important in estab-
lishing the overall weight of evidence for a causal relationship:
temporality, strength of the association, biological gradient (dose
response), consistency of the observations, biological plausibility,
and evidence of recovery. A number of illustrative examples were
presented to demonstrate how the framework would work to eval-
uate hypotheses that particular EDCs cause speciﬁc adverse
outcomes.
The WHO-UNEP 2012 report did not adopt the WHO-IPCS 2002
framework for assessing causation. In fact, the authors criticize the
earlier approach because it failed to distinguish between the qual-
ity of evidence and strength of the recommendations, as recom-
mended in the Grades of Recommendation Assessment,
Development and Evaluation (GRADE) scheme used in clinical
medicine (GRADE, 2011). Despite the reference to this alternative
approach, the 2012 report did not apply the GRADE scheme
(which, because it was derived for clinical medicine, would not
be appropriate in any case for the evaluation of toxicology data
and studies in wildlife). Although there is substantial discussion
of weight of evidence, no systematic approach is described or
adopted to assess the weight of evidence for causation; instead,
‘‘best professional judgment’’ is the basis for making expert assess-
ments of the data and aggregated data are purported to be pre-
sented on trends, biological plausibility, relevant exposures,
consistency across species, dose–response, and temporality
(WHO-UNEP, 2012a, p. 19). However, not all of these categories
are captured in the discussion of all endpoints of concern; in par-
ticular, few data are presented on dose–response. Although a sec-
tion, titled Strength of evidence, is included in the discussion of
health effects and conclusion-like statements are provided for
some adverse health outcomes, in many cases, these conclusions
do not reﬂect the uncertainties or limitations that were described
in the main text. More importantly, these statements do not repre-
sent the totality of the evidence, often ignoring contrary study
results that were inappropriately excluded. Furthermore, little ef-
fort was made to synthesize the ﬁndings across the categories inthe report – from temporal trends to exposure and biological
plausibility – in order to provide a complete picture of the state
of science for MOA, dose response, and adverse health effects.
The use of the narrative approach in the WHO-UNEP 2012 report
allowed for a selective presentation of information without a crit-
ical review of the data. In the absence of a formal assessment of
causation, subjective inference is relied onto suggest causation.
For each of the speciﬁc health or environmental adverse out-
comes discussed, information is presented in the 2012 report for
a sequence of topics in such a way to suggest that they were
related when, often, there is no connection at all. Each subchapter
discusses the trends in the subject disease or health outcome ﬁrst,
followed by a suggestion that exposure to environmental chemi-
cals contributes to these trends. In some cases, limited or no data
are provided to support environmental chemical exposures as
contributing to the trends and often, other causes of the trends
are ignored or dismissed. For example, the report stated that there
is a rising trend for breast cancer and notes that this trend cannot
be explained by improved diagnosis or changes in risk factors,
including genetic factors (WHO-UNEP, 2012a, p. 126). This state-
ment about the trends is followed by the comment that twin stud-
ies have highlighted the importance of environmental factors. The
juxtaposition of these two sentences gives the reader the impres-
sion that the rising trend in breast cancer must be a consequence
of these environmental chemical exposures. However, the term
‘‘environment’’ as used in twin studies encompasses all modiﬁable
(i.e., non-genetic) factors, not just environmental chemical expo-
sures. Several publications have concluded that the observed
increase in breast cancer incidence in some countries can be
explained by the introduction and promotion of mammography
and breast cancer screening (Glass et al., 2007; Séradour et al.,
2009; Weedon-Fekjær et al., 2012). In addition, in several countries
around the world, the trend for breast cancer has been in decline
since 2002, which has been attributed to the dramatic reduction
in hormone replacement therapy in post-menopausal women
(Glass et al., 2007; IOM, 2012; LeClère et al., 2013; Séradour
et al., 2009; Weedon-Fekjær et al., 2012). Therefore, the implica-
tion that the trends are due to environmental chemical exposures
is misleading when evidence for some of the changes in breast can-
cer trends point to improved diagnostic tests or to changes in rec-
ommended post-menopausal therapies. In the IOM (2012) review
of the state of the science regarding environmental risk factors
for breast cancer, the factors with the clearest evidence included:
hormone therapy products, oral contraceptives, being overweight
or obese, alcohol consumption and ionizing radiation; the evidence
for exposure to industrial chemicals was considered to be limited
and in some cases only suggest a possible association for an
increased risk of breast cancer. Further discussion of the issues
associated with disease trends as presented in the WHO-UNEP
2012 report is described in more detail in Section 2.5.
Another part of the discussion in the 2012 report for each ad-
verse outcome included a description of the normal role of endog-
enous hormones. This information is useful in understanding
normal physiology, basic mechanisms and showing the potential
biological plausibility for endocrine disruption; however, it does
not demonstrate that environmental chemicals are acting in the
same manner as endogenous hormones. Evidence is presented
from epidemiology and experimental animal studies for particular
chemicals associated with various health outcomes, but rarely is
there any discussion of speciﬁc mechanisms for the highlighted
chemicals. For example, androgens and estrogens are mentioned
as playing a role in normal prostate development; however, an
androgen- or estrogen-mediated MOA cannot be described for
any chemical mentioned in this section. In fact, the report notes
that ‘‘the precise mechanisms by which the chemicals related to
prostate cancer induce the carcinogenic process remain to be
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that environmental chemicals could cause disease via the same
mechanisms as endogenous hormones without any understanding
of the normal feedback mechanisms that exist for homeostasis as
well as differences in potency and dose–response (discussed in
more detail in Section 2.6). Moreover, a failure to recognize the
complexity of hormone-receptor interaction and activation is lack-
ing. Speciﬁcally, despite a short discussion at the beginning of the
WHO-UNEP 2012 report, the roles of co-activators, repressors, and
transcription factor interactions, and receptor cross-talk are com-
pletely ignored throughout the rest of the report. Recent studies
also point to competition for transcription factors (Kollara and
Brown, 2006); yet these issues are completely overlooked.
Another shortcoming of the WHO-UNEP 2012 report that af-
fects the cohesive evaluation of causation is the fact that little, if
any, discussion of exposure occurred in the report in the context
of speciﬁc effects or related to speciﬁc hormonal MOAs. Generally,
when exposures were mentioned, a reference is made to Chapter 3
of the 2012 report. In Chapter 3, only general information is pre-
sented on major classes of chemicals that the WHO-UNEP 2012 re-
port described as known or potential endocrine disruptors. No
quantitative information on exposure is presented for individual
chemicals, and potential human exposures are not considered in
context of dose–response data. The segregation of exposure data
from the information on chemicals of concern, potential adverse
effects associated with that chemical, and biological plausibility
or possible MOAs for endocrine disruption make the assessment
of the causal relationship between exposure and effects
impossible.
The lack of a systematic approach to assess causation for spe-
ciﬁc chemicals and associated health outcomes resulted in conclu-
sions that were predisposed to the identiﬁcation of potential EDCs.
The selective citation of literature without discussion of contradic-
tory studies and the failure to consider alternative causes of re-
ported effects gives the reader the impression that the weight of
evidence is stronger than is justiﬁed by the available scientiﬁc data.
This calls into question the integrity of decisions at all levels of the
2012 report. Speciﬁc examples are provided below that further
demonstrate the issues with the evaluation of causation in the
WHO-UNEP 2012 report, with an emphasis on highlighting the
key factors that are typically used in a causation assessment.
2.4.1. Adrenocortical hyperplasia in seals
The WHO-UNEP 2012 report concluded that there was sufﬁ-
cient evidence to demonstrate that a mixture of PCBs and DDT
caused adrenocortical hyperplasia and a Cushing-like condition
in Baltic seals. The report attributes recoveries in seal populations
to the ‘‘drastic reduction of DDT and PCBs in Baltic biota’’ (p. 149).
This conclusion is not supported by the discussion in the main text
of the report; at best, it is based on limited data. Additionally, the
report ignores conﬂicting data and fails to consider alternative
causes for the adrenocortical hyperplasia.
The data on adrenocortical hyperplasia in seals or other aquatic
mammals are limited and inconsistent. Although the WHO-UNEP
2012 report mentions that adrenocortical hyperplasia has not been
reported in seal populations outside the Baltic Sea, it does not dis-
cuss evidence from Great Britain that reported contrasting results
for other marine mammals (Kuiken et al., 1993); nor does the re-
port address alternative causes for these observations. For exam-
ple, Kuiken et al. (1993) measured the concentrations of
chlorinated hydrocarbons in the carcasses of harbor porpoises
and found that adrenocortical hyperplasia was not associated with
increased levels of these chemicals, but rather associated with
chronic stressors causing their death (e.g., malnutrition, prolonged
illness). Another study that is not mentioned, Clark et al. (2006),
also found a signiﬁcantly higher adrenal gland mass in Atlanticbottlenose dolphins that were chronically stressed compared to
those that were acutely stressed, suggesting that other factors
may be involved in the observation of adrenocortical hyperplasia
in seals. Lair et al. (1997) suggested that the adrenal hyperplasia
seen in beluga whales may be part of the normal aging process.
Although these latter studies are on cetaceans, rather than pinni-
peds, they point to alternative causes of adrenocortical hyperplasia
in marine mammals and should have been considered in the data
review and assessment of causation.
The report also fails to address data inconsistencies for the spe-
ciﬁc persistent organic pollutants (POPs) mentioned, including the
differences observed between experimental animal studies and re-
ports in wildlife. For example, in two-year chronic toxicity studies
of PCBs conducted in female Sprague–Dawley rats (NTP, 2006,
2010), increased adrenocortical atrophy was reported, which is in
contrast to the ﬁndings of adrenocortical hyperplasia found in Bal-
tic seals. Cancer bioassays for several commercial PCB mixtures
(i.e., Aroclors) do not report adrenal effects in rats exposed to these
PCBs for two years in the diet (Mayes et al., 1998), which further
calls into question the identiﬁcation of PCBs as the cause of adre-
nocortical hyperplasia in seals. While the degree of similarity be-
tween adrenal glands of seals and rats is unknown, it is expected
that similar, rather than opposite, effects from the same chemical
are more likely in mammals. The WHO-UNEP 2012 report
acknowledges in the introduction to the section on adrenocortical
hyperplasia that a DDT metabolite showed degeneration and
necrosis in the adrenal cortex of laboratory mice – a ﬁnding incon-
sistent with hyperplasia – but this is not mentioned further.
No information on plasma cortisol levels is available for the Bal-
tic Sea seals, as the WHO-UNEP 2012 report notes, which are crit-
ical for differentiating a stress response from a direct toxic effect
on the hypothalamus–pituitary-adrenal axis as the cause of the ob-
served hyperplasia (Harvey and Sutcliffe, 2010). Although the
WHO-UNEP 2012 report recognizes the possible role of stress
and aging of wildlife in the development of adrenal hyperplasia
in the main text, when the strength of evidence is described, these
factors are ignored. The 2012 report does not consider alternative
causes for the observed species recovery, and stress can plausibly
explain these observations given other changes occurring during
the same time period in the Baltic Sea (e.g., reductions in nutrient
inputs, eutrophication, oxygen deﬁciency, and oil discharges)
(HELCOM, 2012).
It is presumed that because the effect occurred in an endocrine
organ, this must be the result of endocrine disruption, but no data
are provided to show that these effects are the result of an endo-
crine MOA. Given the limited data available on the observation of
adrenocortical hyperplasia, inconsistent ﬁndings in experimental
animal studies, conﬂicting data in other wildlife species and other
regions, and stress as a plausible alternative cause for these obser-
vations, it is questionable that there is sufﬁcient evidence to dem-
onstrate that these compounds caused the adrenocortical
hyperplasia observed in the Baltic seals.
2.4.2. Prostate cancer
Prostate cancer is included in the discussion of various hor-
monal cancers in the WHO-UNEP 2012 report and it is stated that
there is sufﬁcient evidence for a link between pesticide exposures
and prostate cancer (WHO-UNEP, 2012a, p. 130). However, the re-
port does not reach any conclusions or make any statements about
the evidence for an endocrine-mediated MOA. The mere associa-
tion between pesticides and prostate cancer is insufﬁcient to dem-
onstrate causation. More importantly, this link has not been shown
to be attributable to an alteration in endocrine function. Moreover,
based on the data presented in main text of the report, from an
objective view, there is not sufﬁcient evidence to conclude that a
link between pesticide exposures in general and prostate cancer
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been reported to be associated with prostate cancer; however,
these data are not consistent. For example, the report mentions
that oxychlordane was linked with an increased risk for prostate
cancer based on Ritchie et al. (2003). Another study cited in the re-
port (Hardell et al., 2006) that did not observe an association be-
tween oxychlordane and prostate cancer is ignored. Other
biomonitoring studies that examined oxychlordane levels are not
cited in the 2012 report, including two studies that failed to ob-
serve an association with prostate cancer (Aronson et al., 2010;
Sawada et al., 2010) and one that did (Xu et al., 2010). Thus, the
evidence from biomonitoring studies for an association between
oxychlordane and prostate cancer is inconsistent. In these same
studies, similar results were seen for other organochlorine pesti-
cides where only one or two statistically signiﬁcant associations
were reported for any individual pesticide. Although other epide-
miology studies are cited in the WHO-UNEP 2012 report, these
studies did not directly measure exposure through analysis of
blood, fat, or urine, and therefore, are considered to be more sus-
ceptible to bias and should be given less weight in an overall
assessment of the evidence. For example, the Agricultural Health
Study (AHS) (Alavanja et al., 2003; Koutros et al., 2010) obtained
exposure information based on a questionnaire that collected data
on duration and frequency of pesticide use, which is a less reliable
measure of exposure compared to biomonitoring studies.
It is interesting to note that the two meta-analyses of pesticide
applicators (van Maele-Fabry and Willems, 2004) and pesticide
manufacturers (van Maele-Fabry et al., 2006) characterized the
weight of evidence for pesticide exposure for these workers as
weak (rate ratios of less than two). A general limitation with the
epidemiology studies on pesticide exposure and cancer is the use
of multiple comparisons to assess risks for many different types
of pesticides and various cancer endpoints, which increases the
likelihood that a statistically signiﬁcant association will be de-
tected based on chance alone. In addition, the long latency be-
tween initiation and detection of the cancer make it very difﬁcult
to identify relevant exposures. Overall, the data for pesticides as
a broad category are weak and those for individual pesticides are
limited with regard to an association with prostate cancer,
let alone to causation.
While it has been speculated that hormones play a role in the
development of prostate cancer given the involvement of sex ste-
roids in the development of the prostate, it is recognized that many
other factors may be involved in the etiology of prostate cancer.
These factors include age, family history (genetics), race, dietary
fat, and other dietary factors (NCI, 2013). As the WHO-UNEP
2012 report notes, the mechanism by which pesticides could in-
duce prostate cancer is currently unknown. Therefore, while it
may be biologically plausible for endocrine disruption to be con-
tributing to prostate cancer, insufﬁcient data are available to show
that pesticides are involved in the induction of prostate cancer by
an endocrine-mediated MOA.
Based on the issues discussed above regarding the strength of
the association, lack of consistency among studies of pesticide
workers and manufacturers and lack of evidence for an endocrine
MOA, the overall weight of evidence for pesticides causing prostate
cancer through endocrine disruption should have been determined
to be either inconclusive or weak, not ‘‘sufﬁcient’’ as determined in
the WHO-UNEP 2012 report.
As the above examples illustrate, the WHO-UNEP 2012 report
presented information on chemicals and various adverse out-
comes, but whether these exposures actually cause these effects
was not established scientiﬁcally. Several factors for establishing
causation, such as demonstrating exposure to the chemical,
dose–response, and consistency in the data, were frequently
ignored. Most critically, the lack of a formal framework orstandardized approach to evaluate the data on speciﬁc chemicals
and the potential causal association with adverse outcomes via
an endocrine-mediated MOA is a signiﬁcant shortcoming in the
WHO-UNEP 2012 review.2.5. What do temporal trends in diseases show?
The WHO-UNEP 2012 report indicates that the high incidence
and increasing trends of many endocrine-related disorders in hu-
mans is one of ‘‘three strands of evidence [that] fuel concerns over
endocrine disruptors’’ (p. vii). The report indicates that ‘‘world-
wide, there has been a failure to adequately address the underlying
environmental causes of trends in endocrine diseases and disor-
ders’’ (WHO-UNEP, 2012a, p. ix).
It should be noted that, in some cases, the WHO-UNEP 2012 re-
port does put trends in perspective. For example, the report indi-
cates that elevated BPA levels in the body could be a result of
polycystic ovarian syndrome and not the other way around. In
other cases, however, alternative explanations are either not dis-
cussed, or when they are discussed, they are dismissed in favor
of endocrine disruption as an explanation without a sufﬁcient eval-
uation of the science. For example, as noted earlier, the report
brieﬂy acknowledges, but appears to dismiss, the role of alternative
factors in reported trends for breast cancer or sperm/semen
quality.
The 2012 report concluded that because the increase in disease
trends has occurred primarily over the last few decades, these
trends cannot be entirely attributable to genetic causes. It is im-
plied that if these trends are not the result of genetic heritability,
then the only other explanation is environmental exposure to
chemicals. However, environmental factors go well beyond chem-
icals, and cover a multitude of characteristics in human popula-
tions including: diet, exercise, lifestyle factors, infectious agents,
and even drug use; for wildlife, these include factors related to
habitat, food supply, disease, predation, and competition – factors
which can be completely unrelated to environmental chemical
exposures. The WHO-UNEP 2012 report does not acknowledge
that, much of the time, the environmental causes of the diseases
being discussed are not chemical exposures.
There are many factors that can inﬂuence the appearance of an
increasing trend (either temporally or geographically) in disease
incidence or prevalence. For human health considerations, these
include changes in diagnostic criteria, screening, medical interven-
tions, and treatment. Other life style trends are important; for
example, giving birth at an older age can have a substantial impact
on the incidence of birth defects and congenital abnormalities.
Another signiﬁcant trend is the obesity epidemic and being
overweight has been found to increase the risk of male infertility
(Hammoud et al., 2008). In addition, the report sometimes de-
scribed trends based on a compilation of data from different
sources such that, what appears to be a trend actually may be a
reﬂection of different data collection methods.
Through selective citation in the WHO-UNEP 2012 report, an
impression is created that certain diseases have an increasing inci-
dence or prevalence. However, publications that are not cited in
the WHO-UNEP 2012 report often provide opposing evidence that
the occurrence of the disease of interest is not on the rise. For
example, in the 2012 report, several papers are cited to indicate
that the prevalence of hypospadias is increasing. Fisch et al.
(2010) was not cited, who stated that ‘‘[a] review of the epidemi-
ologic data on this issue amassed to date clearly demonstrates that
the bulk of evidence refutes claims for an increase in hypospadias
rates.’’ The postulated decreasing trends in semen quality have also
been highly contested by other scientists, as already discussed
above.
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come trend are related spatially or temporally in an ecological epi-
demiology study, all one can be sure of is that a statistical
correlation exists. Such study designs cannot determine whether
people with health effects are the same people with a particular
exposure in these studies. In addition, it generally cannot be
known if the exposure occurred before the health outcome (or vice
versa), whether they each have a common cause, or whether they
are completely independent. As a result, these analyses are the
weakest form of scientiﬁc evidence for evaluating causation.
The reasoning presented in the WHO-UNEP report that the ris-
ing disease trends must be associated with exposure to EDCs be-
comes even more questionable given that exposure to most of
the compounds named in the report have not increased over the
last twenty or thirty years, but rather, have decreased. Concentra-
tions of DDE in human milk in Germany have been reported to be
reduced by approximately 90% from 1984 to 2001 (Wilhelm et al.,
2007). Another biomonitoring study in Germany clearly shows that
human exposure to phthalates has declined over time, with the
exception of some new compounds that were recently introduced
to the market (Wittassek et al., 2007). Historical biomonitoring
data from a number of countries including the Czech Republic,
Norway, and the U.S. indicates that human exposure to compounds
like persistent chlorinated pollutants has decreased in the last two
decades (Cerná et al., 2012; Ferriby et al., 2007; Nøst et al., 2013).
These trends in declining human exposures over the last two dec-
ades in the Western world contradict the hypothesis presented in
the WHO-UNEP 2012 report that a continuing rise in disease
trends, if any, can be related to EDC exposure in humans.
Overall, any claims of trends indicating an endocrine cause
must be supported by a systematic review of all relevant data
regarding disease trends, exposure trends, and alternative explana-
tions for observed statistical correlations. Below, two examples are
discussed in which theWHO-UNEP 2012 report described trends of
increasing endocrine-related disorders and concluded they are due
to environmental EDCs, without considering whether the weight of
evidence supports such conclusions or alternative explanations are
more likely. Note that these examples are not weight-of-evidence
analyses, but the identiﬁcation of factors and limitations related
to the discussion of health trends in the WHO-UNEP 2012 report
and how these factors may lead to erroneous conclusions.
2.5.1. Autism spectrum disorders (ASDs)
Autism spectrum disorders (ASDs) – which include autistic dis-
order, Asperger’s syndrome, and pervasive developmental disor-
ders not otherwise speciﬁed – are developmental disabilities that
are diagnosed based on behavioral symptoms and failure to reach
certain developmental milestones (CDC, 2012). ASDs are character-
ized by communication and socialization problems, as well as
atypical behaviors and interests. ASD symptoms are usually appar-
ent before the age of three and can vary in severity and presenta-
tion. While IQ decrement can co-occur with ASDs, they are not
associated with ASDs per se (CDC, 2012).
The WHO-UNEP 2012 report claims that ‘‘the increase in autism
spectrum disorders is indisputable’’ (p. 109) and there is ‘‘sufﬁcient
evidence to conclude that a number of factors, including environ-
mental, contribute to the increases in autism spectrum disorders’’
(p. 119). The ﬁrst claim is based on two studies, one published in
1976 and the other in 2007 (Rice, 2007; Wing et al., 1976). More
current analyses were not cited; there is a considerable body of
other literature evaluating ASD prevalence that the WHO-UNEP
2012 report did not consider.
At least some of the increase in ASD prevalence is due to
changes in diagnostic criteria, better diagnostic techniques and in-
creased case ascertainment (CDC, 2012). For example, when the
Centers for Disease Control and Prevention (CDC) created newdiagnostic standards for its Autism and Developmental Disabilities
Monitoring Network (ADDM), there was a signiﬁcant increase in
ASD prevalence compared to the prevalence estimated using older
standards (Rice et al., 2012). Also, a recent reanalysis of older stud-
ies found ASD prevalence to be consistent with current reports
when the data were analyzed according to contemporary diagnos-
tic criteria, indicating that ASD was likely underestimated in earlier
studies (Duchan and Patel, 2012). Increases in ASD prevalence may
also be partly attributed to diagnostic substitution, as children who
would have been diagnosed with learning disabilities or mental
retardation in the past are currently diagnosed with ASD (reviewed
by Fombonne et al., 2009). ASD diagnosis relies on behavioral iden-
tiﬁcation, which leaves room for wide variation in clinical judg-
ment and is inﬂuenced by differing cultural and social norms
worldwide (Elsabbagh et al., 2012). Even within a culture, there
is evidence of low inter-evaluator agreement about diagnoses,
although it is not clear in which direction it would inﬂuence
prevalence measures (Duchan and Patel, 2012). Finally, the success
of national awareness efforts and the growth of alternative treat-
ments may also contribute to a perceived increase in ASD preva-
lence, with more children being tested, diagnosed, and treated
(Duchan and Patel, 2012). Therefore, it is not clear that there is a
true increase in ASDs.
Regardless of temporal trends, the WHO-UNEP 2012 report pre-
sents no evidence that environmental factors, much less EDCs,
contribute to ASDs. The report summary stated that ‘‘insufﬁciency
of thyroxine during pregnancy is also associated with reduced
intelligence quotient, ADHD and even autism in children’’ (p. xii).
Yet, the WHO-UNEP 2012 report does not provide a reference to
support this claim, nor discuss any other factor(s) that may con-
tribute to ASDs. There is no clear etiology for autism and no known
MOA for it being induced, thus the current science cannot substan-
tiate endocrine disruption as causal. Many potential non-EDC risk
factors have been studied, including genetics, older paternal age,
sex, prenatal nutrition, and in utero exposure to antidepressants
and pain-killers (e.g., Duchan and Patel, 2012; Gentile et al.,
2013; Guinchat et al., 2012; Kinast et al., 2013; Schmidt et al.,
2011). Although the weight of the evidence supporting these
associations varies, the available data indicate that a good deal of
research on possible causes of ASDs is not considered in the
WHO-UNEP 2012 report.
Overall, the two references (Rice, 2007; Wing et al., 1976)
regarding endocrine disruption and trends reported for ASDs on
which the WHO-UNEP 2012 report relies are not representative
of the literature as a whole. Thus, the report’s conclusions that
there are actual increases in the spectrum of autism-related disor-
ders and that these increases are due to endocrine disruption are
not supported based on the current state of the science.2.5.2. Wildlife population declines
The WHO-UNEP 2012 report stated that the evidence for ‘‘endo-
crine disrupting POPs such as PCBs and organochlorines’’ (p. 186)
as causes of wildlife population declines has increased since
2002 due to observed increases in the populations since restric-
tions on the use of these chemicals. The logic presented – that as
chemical exposures increased, populations declined and,
conversely, as chemicals were removed from the market and as
exposures declined, populations recovered, would be reasonable
if: (1) the chemical exposures are documented; (2) the levels of
exposure occurring are sufﬁcient to impact the organisms; (3)
the organism-level impacts are manifested in population-level im-
pacts; and (4) other possible causes for population changes are
adequately considered. The WHO-UNEP 2012 report falls short in
demonstrating the linkages that would be required to make a case
based on all of these points.
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2012 report are links between DDT and bird populations and be-
tween tributyl tin (TBT) and snail populations. For the latter exam-
ple, the report cites publications by Jörundsdóttir et al. (2005) and
Morton (2009). Jörundsdóttir et al. (2005) observed reductions in
the levels of imposex in the dogwhelk (Nucilla lapillus) in Iceland,
mainly near small harbors with no change seen in larger harbors.
As no measurements were made of TBT concentrations,
Jörundsdóttir et al. (2005) stated that the continued impacts in
the large harbors are ‘‘presumably associated’’ with continued
use of TBT paints on larger vessels. Morton (2009) documented a
20-fold increase in the population of N. lapillus on the southeastern
coast of England during the period May 2004–August 2008, which
coincided with the period over which TBT was banned as an anti-
foulant paint globally. Morton (2009) stated that, ‘‘due to the lack
of conﬁrmatory chemical data, the changes in population size,
structure, and reproduction herein reported upon for N. lapillus
cannot be correlated positively with changes in ambient TBT lev-
els.’’ The WHO-UNEP 2012 report discusses recovery in the abun-
dance of North Sea brown shrimp, although there is no known
mechanism of endocrine disruption by TBT in crustaceans. Verhae-
gen et al. (2012), as cited in the WHO-UNEP 2012 report, state that
the inability to demonstrate an ‘‘unarguable causative link’’ be-
tween decreased organotin concentrations and recovery of the
shrimp stock is due to the lack of data on both exposure and effects
in these organisms. None of these weaknesses in the conclusions of
the cited studies are mentioned in the WHO-UNEP 2012 report,
and therefore, the observed trends of imposex and the recovery
of snail and shrimp populations cannot be deﬁnitively attributed
to TBT, much less endocrine disruption.
Although the ability of organotins to cause masculinization of
female gastropods (including the development of imposex) is prob-
ably the most-recognized EDC effect in wildlife over the past 30+
years, the vast majority of ﬁeld studies on this phenomenon do
not include chemical analyses of body burdens (Titley-O’Neal
et al., 2011). This review article by Titley-O’Neal et al. (2011) is ci-
ted in the WHO-UNEP 2012 report, but a number of interesting
points from the review were not mentioned. For example, the
WHO-UNEP 2012 report does not note the lack of agreement
among researchers on the mechanism for induction of effects, the
observation of imposex prior to the use of TBT, the natural occur-
rence of imposex in some species, the lack of sensitivity of a num-
ber of species to TBT-induced imposex, and the fact that female
masculinization by TBT or triphenyl tin (TPT) has been conﬁrmed
in the laboratory in only a small fraction of species affected (7.5%
or 20 species conﬁrmed out of 268 total species examined). Thus,
the statement in the WHO-UNEP 2012 report that the ‘‘temporal
relationship between a measure of exposure and population
parameters’’ for TBT as an example of the ‘‘best evidence of a rela-
tionship between EDCs and wildlife populations,’’ does not reﬂect
the uncertainties in the available information, including the stud-
ies cited in the report.
The WHO-UNEP 2012 report acknowledges the difﬁculty in
making the link between declines/recoveries in wildlife popula-
tions and EDCs, stating that many factors may be responsible.
These factors may include food, habitat, competition, predation,
overall environmental quality, climate change, and human activi-
ties (e.g., harvesting, trafﬁc, noise). Regardless, the report empha-
sizes chemicals, speciﬁcally EDCs, as the main causative factor.
Even in the case of TBT and N. lapillus, which is arguably the best
known example of EDC effects on wildlife, there are other factors
that impact the distribution and abundance of this gastropod. This
species is sensitive to changes in nutrient levels, substrate loss,
toxic algal blooms, and oil spills (Bryan, 1968; Gibbs et al., 1999;
Robertson, 1991). For the DDT example cited in the WHO-UNEP re-
port, a number of confounding factors are likely to have affectedthe recovery of osprey populations, as discussed by Henny et al.
(2010), who stated that ‘‘expansion of suitable habitat (reservoirs)
and enhanced use of artiﬁcial nest sites confounds a simple conclu-
sion that recent population increases were solely a recovery from
earlier contaminant exposure,’’ especially in the western United
States. The WHO-UNEP 2012 report concluded that the ‘‘strength
of the evidence linking EDC exposure to most wildlife population
declines is insufﬁcient,’’ then goes onto make the statement that
‘‘an endocrine mechanism for wildlife declines is probable but
not conclusive’’ (p. 186). It would be more appropriate to conclude
that the evidence for an endocrine mechanism is hypothetical, par-
ticularly given the fact that for the two best known examples for
wildlife declines, DDT and TBT, an endocrine mechanism, while
possible, is only one of many potential factors that may be contrib-
uting to the observed population dynamics.
2.6. Importance of dose–response and potency
In Chapter 1 of the WHO-UNEP 2012 report, an effort is made to
describe the endocrine system in general – the glands involved,
hormones produced, molecular mechanisms involved in mediating
responses, and the physiological processes that are regulated by
this system. A few of the feedback mechanisms that are an integral
part of this system (e.g., how insulin secretion is affected by
changes in blood glucose levels) are also mentioned. These various
negative feedback loops are important in regulating the production
and release of hormones, the expression of various hormone recep-
tors, and generally maintaining homeostasis (i.e., a stable internal
environment). What the WHO-UNEP 2012 report fails to fully dis-
cuss, however, is the fact that the endocrine system is speciﬁcally
designed to respond to environmental ﬂuctuations and such
homeostatic responses generally are considered normal, adaptive,
and necessary as long as they are transient and within the normal
homeostatic range (Goodman et al., 2010; Rhomberg et al., 2012).
In fact, the responsive nature of the endocrine system is essential
to health as seen in the hormonal changes that occur when a wo-
man becomes pregnant. In other words, not all modulations of
endocrine function are necessarily adverse. Based on this fact, it
can be generally accepted that endocrine activity observed through
in vitro testing (or even some in vivo assays) is not sufﬁcient to
classify a substance as an endocrine disruptor if these tests do
not address whether the alterations cause actual harm in a whole
organism or its offspring. Rather, such a substance may be consid-
ered endocrine-active only (EFSA, 2013a); without a clear indica-
tion of consequent adversity in a living organism, the substance
does not reach the level of an endocrine disruptor. Nevertheless,
the WHO-UNEP 2012 report often presented evidence of in vitro
or in vivo endocrine modulation (rather than adversity) as support
for certain substances being classiﬁed as EDCs. For example, in the
section on adrenal disorders, only in vitro data are presented as evi-
dence of potential endocrine disruption in humans; no epidemiol-
ogic evidence of adrenal effects in people is available. Given the
fact that a large proportion of the cited in vitro studies relate to
alterations in gene expression, the data presented fall short of
demonstrating an adverse effect and are not sufﬁcient for estab-
lishing endocrine disruption. Despite the lack of robust evidence
for adrenal disorders in humans as a result of exposure to environ-
mental chemicals, the WHO-UNEP 2012 report identiﬁed the adre-
nal cortex as ‘‘the most commonly affected and vulnerable
endocrine organ in toxicology’’ (p. 148).
The WHO-UNEP 2012 report contends that hormonal dose–re-
sponse curves are non-monotonic and states that NMDRs for EDCs
are to be expected. As support for NMDRs, theWHO-UNEP 2012 re-
port cited a recent review by Vandenberg et al. (2012) in which
numerous examples were presented of EDCs that exhibit these
types of behaviors. This review has been duly criticized, however,
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and the general acceptance of those studies that do show these
types of responses without any type of critical evaluation of study
quality; the inclusion of studies that do not address adverse effects,
but rather, transient, adaptive responses; and a failure to consider
whether the doses examined in these studies are of any relevance
to human exposure levels (Rhomberg and Goodman, 2012).
The Danish Centre on Endocrine Disrupters, in its examination
of the evidence presented by Vandenberg et al. (2012) for NMDRs,
noted that the majority of these data were from in vitro studies and
inappropriately included ﬁndings for which the U-shaped or in-
verted U-shaped curves were the product of general toxicity
(DTU Food, 2013). It was concluded that 45% of the in vitro exam-
ples cited by Vandenberg et al. (2012) were the result of cytotoxic-
ity and thus were not examples of true NMDRs. Of the remaining
examples cited, approximately one-third were judged to be false
and another one-third were considered questionable. Further, only
5 of the 34 in vivo examples cited by Vandenberg et al. (2012) were
considered to show ‘‘clear evidence’’ of NMDRs. In other words,
while examples of NMDRs do exist, they are not as common as
Vandenberg et al. (2012) suggests. Recently, USEPA also conducted
an expert review of the experimental evidence for NMDRs (USEPA,
2013). In this draft report, EPA noted that such responses are not
uncommon in in vitro studies and often relate to ‘‘lower-order bio-
logical endpoints’’ rather than apical endpoints. However, ‘‘[t]here
is currently no reproducible evidence that the early key events in-
volved in the expression of NMDRs that are identiﬁed at low doses
are predictive of adverse outcomes that may be seen in humans or
wildlife populations for estrogen, androgen or thyroid endpoints’’
(USEPA, 2013, p. 8). USEPA concluded that, while NMDRs for ad-
verse effects have been occasionally seen in intact organisms,
NMDRs are relatively uncommon. Further, such dose–response
curves – when observed – typically occur at high doses, well above
the NOAELs identiﬁed in standard testing paradigms. In summary,
the limited available evidence for low dose effects and NMDRs
does not preclude the need to consider dose in assessing the poten-
tial hazards of chemicals to the endocrine system.
The WHO-UNEP 2012 report also asserts the potential for EDCs
to act at very low doses (i.e., doses below the no observed adverse
effect level [NOAEL] or doses below a dose that is environmentally
relevant to humans). The implication is that no threshold can be
characterized for adverse effects; therefore, any exposure poses
some kind of concern, though the magnitude of the effect, or even
its direction, let alone its adversity, is not considered relevant from
this perspective. However, there are many reasons to question the
assertion of effects at very low doses. First, as noted by EFSA
(2010), studies of low-dose effects often suffer from various meth-
odological shortcomings (including the use of small numbers of
animals and single doses). Additionally, their ﬁndings are of ques-
tionable toxicological relevance and frequently cannot be repli-
cated in subsequent, more robust studies (EFSA, 2010).
Second, the WHO-UNEP 2012 report generally does not address
the fact that many EDCs have much lower potency than endoge-
nous hormones (Nohynek et al., 2013; Sharpe, 2003). In fact, the re-
port claimed that in the diethylstilbestrol (DES) case study, while
other chemicals may be less potent than DES, these effects are
‘‘equally undesirable when the exposure occurs in early develop-
ment where potency seems less important’’ (WHO-UNEP, 2012a,
p. 25). In other words, the report suggests that at vulnerable devel-
opmental stages, potency may not be very relevant. This statement
confuses the issue of potency and sensitivity at different life stages.
Although certain substances may be more or less potent depending
on the particular life stage at which exposure occurs, potency is al-
ways important – no matter the developmental window. The
WHO-UNEP 2012 report rightly stated that hormone potency and
receptor afﬁnity are not the same things (p. 12). It is further sug-gested that potency depends on many different factors, but it is va-
gue as to what those factors might be (other than receptor
abundance). At the receptor level, potency is determined by both
the afﬁnity of a substance to bind to a receptor site as well as
the efﬁcacy with which that substance activates the receptor
(Borgert et al., 2013). Endogenous hormones have both strong
afﬁnity for their receptor sites as well as high efﬁcacy for activation
of these receptors; thus, hormones generally are highly potent for
modulating endocrine function. Exogenous chemicals, on the other
hand, are rarely as potent as hormones, either due to reduced afﬁn-
ity, reduced efﬁcacy, or both (e.g., Gaido et al., 1997; Nilsson,
2000). Although the WHO-UNEP 2012 report claims that ‘‘very
low concentrations of environmental endocrine disruptors could
add to the endogenous hormone effect to produce a response that
is much greater than would be predicted based on the hormone
alone’’ (p.8), this theory fails to consider the existence of biological
thresholds. As described by Borgert et al. (2013), given the lower
potency of most exogenous chemicals, the additional presence of
these chemicals will not signiﬁcantly alter hormone receptor occu-
pancy; thus, a biological threshold for potency exists.
At the whole organism level, potency relates to the ability of a
substance to produce a biological effect and may be substantially
different from the potency measured with in vitro assays (EFSA,
2013a). In considering potential EDCs, therefore, potency should
not be determined based on the results of in vitro studies. Rather,
EFSA recommends that potency should be based on the ability of
a substance to produce an adverse health effect in vivo (EFSA,
2013a). This ability will depend on not just a substance’s potency
at its receptor site, but also on its disposition in the body, the tim-
ing of exposure (i.e., the particular life stage of development) and
the dose and duration of exposure. Therefore, dose remains an
important factor in assessing the potency of potential EDCs to
cause adverse health effects.
Endocrine disruption is generally posited throughout the WHO-
UNEP 2012 report in terms of ‘‘adverse’’ outcomes, yet the report
fails to provide a concrete deﬁnition for what may be considered
an adverse response. In particular, the 2012 report did not adopt
the IPCS (2004) deﬁnition of an adverse health effect: ‘‘change in
morphology, physiology, growth, development, reproduction or
life span of an organism, system, or (sub) population that results
in an impairment of functional capacity, an impairment of the
capacity to compensate for additional stress, or an increase in sus-
ceptibility to other inﬂuence.’’ The need to clearly delineate ad-
verse from adaptive responses, particularly when considering
results from in vitro assays, was addressed and possible deﬁnitions
for these terms proposed in a recent workshop (Keller et al., 2012).
Certain endocrine-mediated adverse effects – such as cancer or
reproductive disorders – clearly can be judged as detrimental.
For other endpoints – such as alterations in hormone levels – it
is more difﬁcult to delineate an adaptive response that is within
the limits of homeostasis from one that has gone beyond those lim-
its for a sufﬁcient period of time and, therefore, capable of causing
an adverse effect. This is particularly true when hormone levels are
only measured at a single time point shortly after exposure with no
indications of whether the response is transient or more perma-
nent. Thus, the mere presence of a change does not necessarily
mean that the outcome is adverse. For example, in the discussion
on thyroid-related disorders and diseases (WHO-UNEP, 2012a, p.
97), the report suggests that chemicals can interfere with thyroid
hormone signaling without affecting serum hormone levels, but
it is stated that methods to evaluate this are not yet available.
Changes in thyroid hormone signaling alone cannot be character-
ized as adverse without evidence to show that these changes lead
to impairment in function (Bianco and Kim, 2006). Furthermore,
the failure to observe changes in serum thyroid hormone levels
would indicate a lack of consequence from the change in signaling.
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endocrine disruptors, EFSA speciﬁcally discussed a ‘‘threshold of
adversity,’’ noting that toxicologically relevant responses occur
only when the degree of endocrine modulation elicited is beyond
that which could be counteracted through homeostatic mecha-
nisms (EFSA, 2013a). These thresholds are similar to those that
exist for responses measured from other physiological systems
operating within the body. Further, their importance in character-
izing endocrine disruption has been emphasized by toxicologists
concerned about the European Commission’s recommendations
for the regulation of EDCs (Dietrich et al., 2013). In contrast, the
WHO-UNEP 2012 report proposes that thresholds for endocrine
disruption ‘‘should not be assumed’’ (p. 19) and exposures to endo-
crine-active substances – no matter the level – will add to the
already present hormone levels in the body and thus alter endo-
crine function in a threshold-independent manner. However, using
mathematical calculations within a systems biology construct,
Borgert et al. (2013) have posited that the endocrine system is able
to discriminate potent hormonal signals from the ‘‘background
noise’’ of other endogenous molecules, making the system
relatively robust in its responses and resistant to spurious interfer-
ences by substances with lower potency.
Because thresholds exist, not only for inducing an endocrine re-
sponse, but also for moving beyond adaptive modulation toward
adversity, it is important to understand at what doses the observed
responses occur and how these doses compare to the levels at
which people or wildlife are typically exposed. In the discussions
in Chapter 2 of the report regarding various adverse outcomes,
however, the WHO-UNEP 2012 report often fails to mention the
doses at which ﬁndings are observed. It is important to note that
doses administered in experimental animal studies are often
orders of magnitude above those to which people or wildlife are
generally exposed. Frequently, if one delves deeper into the scien-
tiﬁc literature as seen in the examples below, it is apparent that the
doses associated with the reported ﬁndings are extremely high,
well above those to which people or wildlife may be typically
exposed.
It is unclear why the WHO-UNEP 2012 report fails to consider
dose in the discussions of evidence for endocrine disruption in hu-
mans and wildlife. In the beginning of Chapter 2 of the report, it is
noted that the focus was on the ‘‘identiﬁcation of the characteris-
tics of the hazards posed by endocrine disruptors rather than risk
assessment,’’ (WHO-UNEP, 2012a, p. 23) because accurate risk
assessments are difﬁcult in light of limited human exposure data
and the combined effects of mixtures. However, the report often
draws conclusions that appear to go beyond a simple assessment
of potential hazard. For example, the report concluded that envi-
ronmental exposures play a role in the observed increased inci-
dences of hormonal cancers — rather than saying that these
exposures have been associated with the cancers (WHO-UNEP,
2012a,b, p. 137). Similarly, the report states that adrenal changes
seen in Baltic seals were caused by exposure to DDT, PCBs, and
their metabolites — instead of saying that they have been associ-
ated with these exposures (WHO-UNEP, 2012a, p. 147). Further,
at the end of Chapter 1, the WHO-UNEP 2012 report stated that
‘‘best professional judgment was used to make expert assessments
of the data linking exposure to chemicals with each disease/
dysfunction,’’ (p. 19) and relevant exposures and dose–responses
were considered. Therefore, although dose and exposure were
speciﬁed as important factors in the evaluation of endocrine
disruption, in reality, this does not appear to have been the case.
To illustrate, a few selected examples are discussed below.
These are not isolated examples, but rather, representative of
how the lack of the consideration of dose in the WHO-UNEP
2012 report leads to a false impression that humans are at risk of
endocrine effects from their daily exposures to chemicals.2.6.1. DES or genistein and endometrial cancer
In the discussion of animal studies of EDCs and endometrial
cancer, the WHO-UNEP 2012 report cites the study of Kabbarah
et al. (2005) as showing ‘‘[g]reater than 90% of CD-1 pups neona-
tally exposed to DES or the phytoestrogen genistein develop
endometrial cancer by 18 months of age whilst C57Bl/6 mice are
resistant’’ (WHO-UNEP, 2012a, p. 130). In this study, both DES
and genistein were injected subcutaneously into the pups (a route
of administration not relevant to environmental exposures for hu-
mans) at doses of 1 and 50 mg/kg/day, respectively, on postnatal
days 1–5. The DES dose is over 1000-fold higher than the typical
estrogen dose that women receive from low-dose daily oral contra-
ceptive pills (Kripke, 2005). Further, the daily intake of genistein in
Japanese subjects, a population known to have high intake of soy
isoﬂavones, has been shown to be <1 mg/kg/day (Nakamura
et al., 2000; Wakai et al., 1999), at least 50-fold lower than the dose
administered to mice in Kabbarah et al. (2005). Thus, the doses of
DES and genistein used in this study are well beyond those to
which people would be typically exposed. Another issue is that this
study was actually conducted in knockout mice with a genetic
predisposition for DNA repair errors – a fact that is not mentioned
in the WHO-UNEP 2012 report and that further brings the human
relevance of the ﬁndings into question.2.6.2. PCBs and neurodevelopmental effects
In another example, in the discussion on neurodevelopmental
disorders, the WHO-UNEP 2012 report cites three studies as
consistent evidence that ‘‘PCB exposures decrease serum thyroid
hormone levels,’’ (p. 113) with no mention of study details. How-
ever, the doses at which effects were observed in those studies
are extremely high. In Goldey et al. (1995) and Zoeller et al.
(2000), rats were exposed to 1, 4, or 8 mg/kg/day of Arochlor
1254 on gestational days 6–21. Although circulating T4 levels were
reduced on postnatal days 1–30, they recovered by postnatal day
45, indicating a transient effect. More importantly, Goldey et al.
(1995) reported that pup mortality was 20% and 50% in the 4
and 8 mg/kg/day dose groups, respectively, indicating that these
doses were extremely high. In the third study (Bastomsky, 1974),
adult rats were injected with an even higher dose of 25 mg/kg/
day of Arochlor 1254 for 4 days. In contrast, the mean intake of
PCBs from consumption of the French diet was recently estimated
at 2.71 ng/kg/day for adults and 3.77 ng/kg/day for children (Sirot
et al., 2012), while that from consumption of the Japanese diet
was estimated at 1.45–2.08 pg/kg/day (Nakatani et al., 2011). Thus,
human exposures to PCBs in the diet are over 300,000 times lower
than the doses used in the experimental studies (on a human
equivalent dose basis) cited in the WHO-UNEP 2012 report as
consistent evidence of effects of PCBs on thyroid function. This dra-
matic difference in dose calls into question the relevance of these
studies to human environmental exposures.
It should be further noted that, although the thyroid develops
and functions in a manner generally similar between rodents and
humans, differences exist that make neonatal rats more suscepti-
ble and less capable of compensating for possible alterations in
function than humans. For example, the human fetal pituitary
can respond to thyrotropin-releasing hormone (TRH) as early as
gestation week 25 and thyroid-stimulating hormone reaches peak
serum levels somewhere around this same time, while the hypo-
thalamic-pituitary-thyroid axis in rats does not respond to TRH
signals until a couple of weeks after birth (Howdeshell, 2002).
Further, free thyroid hormone levels can be maintained during
pregnancy in humans via increased peripheral metabolism and en-
hanced thyroid hormone binding to serum proteins (Ahmed et al.,
2008; Howdeshell, 2002). Consequently, children with congenital
hypothyroidism may be born with low-normal concentrations of
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(Ahmed et al., 2008).2.6.3. BPA and adverse effects
Throughout the WHO-UNEP 2012 report, BPA is mentioned as
being responsible for a variety of adverse ﬁndings in rodents,
including ﬁbroid development in mice and rats (p. 42); defemini-
zation and other alterations in social behaviors in female rats (p.
115); altered mammary gland development leading to increased
tumor induction (p. 128); endometriosis in offspring of exposed
mice (p. 130); and modiﬁed immune responses in mice (p. 169),
to name a few. In all of these cases, the doses of BPA associated
with these ﬁndings are not reported. Further, in Chapter 3 of the
WHO-UNEP 2012 report, the various ways in which people may
be exposed to BPA are emphasized (e.g., in the call-out box on page
196 under the heading called ‘‘origin and use’’). The report also
notes that BPA is found in virtually all people (WHO-UNEP,
2012a, p. 225), but no information is provided on the magnitude
of exposures, the biological concentrations that have been
measured in people, or whether these would be sufﬁcient to cause
adverse effects. The implication is that people are at risk of adverse
health effects because they are exposed to BPA. However, a number
of recent weight-of-evidence evaluations have been conducted to
assess the potential risks to humans from BPA exposure (EFSA,
2013b; Goodman et al., 2006, 2009; Hengstler et al., 2011;
Teeguarden and Hanson-Drury, 2013). These reviews document
that some BPA results reported in investigatory experiments have
not been replicated in subsequent studies and that many studies
have used non-oral exposure routes that bypass ﬁrst-pass liver
metabolism and thus are not relevant to human oral exposures.
The majority of BPA studies have been conducted at doses well
above those to which humans are generally exposed and human
exposures are generally well below the current BPA tolerable daily
intake (TDI) of 0.05 mg/kg/day derived from two- and three-gener-
ation reproductive studies in rodents. More speciﬁcally, daily BPA
exposures were recently estimated by EFSA (2013b) to be
6857 ng/kg/day for toddlers and 6495 ng/kg/day for infants
1–5 days of age; these values are 50- to 100-fold lower, respec-
tively, than the BPA TDI value of 0.05 mg/kg/day. Daily BPA expo-
sures were also estimated by the U.S. Food and Drug
Administration (USFDA) to be 100–200 ng/kg/day for children
and adults and 200–400 ng/kg/day for infants (USFDA, 2009); these
values are even lower than those estimated by EFSA. In other
words, the implication of human health risks from BPA exposure
raised in the WHO-UNEP 2012 report is unfounded when the data
are considered in the context of actual doses administered and
concentrations to which people are typically exposed.
These examples demonstrate that dose was not considered in
the discussion of experimental animal studies in the WHO-UNEP
2012 report. In all of the illustrated cases, potential human expo-
sures are orders of magnitude lower than those administered in
toxicology studies. In addition, some of these studies utilized
routes of exposure (i.e., injection) that bypass normal metabolism
and elimination of chemicals and therefore, are not relevant for
assessing potential environmental exposure to humans. Further,
the WHO-UNEP 2012 report did not address other dose-related is-
sues such as thresholds for effects and potency, when discussing
speciﬁc chemicals.3. Conclusions
The WHO-UNEP 2012 state-of-the-science report on endocrine
disruptors is purported to be an update of the WHO-IPCS 2002
state-of-the-science report – however, it is neither a state-of-the-
science review, nor is it an update of the 2002 report.The 2012 report cannot be characterized as a state-of-the-sci-
ence review because it lacks several key features for this type of
assessment including: the lack of a deﬁned scope for the review,
the absence of a process for identiﬁcation, integration, and inter-
pretation of data, the lack of a structure for evaluating individual
studies for relevance and reliability, and an objective method for
evaluating the weight of the evidence. These deﬁciencies under-
mine the conclusions reached in the report. The WHO-UNEP
2012 report can be more appropriately characterized as a selected
discussion of aspects of science that should be considered when
discussing endocrine disruption, but it is not a summary of the
current state of the science.
Neither can the WHO-UNEP 2012 report be considered an up-
date to the WHO-IPCS 2002 report because it does not build on
and modify the earlier analysis, giving reasons and support for
the changes in the state of the science. A true update to the earlier
report would cite the 2002 conclusions, articulate what data, ﬁnd-
ings, or new understanding since 2002 should be considered and
evaluate how and whether the 2002 conclusions need to be mod-
iﬁed in light of the newer information. In addition, the WHO-UNEP
2012 report does not address research recommendations from the
earlier report. In some cases, the 2012 report reviews the same
data from the 2002 report, but reaches conclusions that conﬂict
with those of the earlier report, despite the lack of new information
to support a change in the weight of evidence. The fact that the
2012 report reaches more deﬁnitive conclusions based on the same
data emphasizes a reliance on subjective decision making and less
stringent criteria for evaluating potential causal relationships com-
pared to the earlier 2002 report. Although theWHO-UNEP 2012 re-
port is stated to be an update, this report in actuality is a revised
review of the state of the science that does not build upon what
was previously done and disregards the WHO-IPCS 2002 proposed
framework for causation in favor of ‘‘best professional judgment’’
on these matters.
A key concern with the WHO-UNEP 2012 report is the use of
subjective inference instead of a formal framework to assess the
potential role of causation for endocrine disruption. The report
adopted a narrative approach for the data review that does not rep-
resent a weight-of-evidence assessment. Rather than demonstrate
causation, the report relies on inference to suggest that exposures
to chemicals and adverse outcomes are related. The WHO-UNEP
2012 report presented information on chemicals and various ad-
verse outcomes, but whether the exposure causes these effects
was not determined or adequately considered in an objective,
transparent, and scientiﬁc manner. Several key factors for estab-
lishing causation, such as a demonstrated exposure to the chemi-
cal, dose–response, and consistency in the data were frequently
ignored. For example, temporal trends in human diseases or wild-
life populations are presented without consideration of alternative
explanations for these trends (especially diagnostic criteria and
reporting changes). Exposures to chemicals considered to have
the potential for endocrine disruption exist and are suggested as
contributing to the observed trends, but there is little consider-
ation of whether these exposures are sufﬁcient to explain the
alleged effects and whether the patterns of exposure are congruent
with the trends. Above all, the lack of a framework to collectively
evaluate, in an objective and comprehensive manner, the data on
speciﬁc chemicals and the alleged adverse outcomes is a signiﬁcant
shortcoming in the WHO-UNEP 2012 review.
The WHO UNEP 2012 report fails to fully address a number of
critical factors that must be considered when deﬁning EDCs;
speciﬁcally dose, dose–response, potency, and adversity. First, the
substance must be shown to cause an adverse effect in an intact
organism, their progeny or (sub)populations; therefore, in vitro
data alone are insufﬁcient for classifying a compound as an endo-
crine disruptor. Further, the observed effect must be shown to go
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result in an adverse outcome. Second, thresholds exist for inducing
such adverse effects. The 2012 report does not give appropriate
consideration to thresholds and dose–response for adverse effects.
Despite the chosen deﬁnition of endocrine disruption as producing
adverse changes, the report treats all effects as evidence of disrup-
tion and makes an a priori rejection of thresholds. Where examples
from animal testing are discussed there is little consideration of
dose–response, when, in fact, only some doses of some compounds
can cause endocrine disruption in the laboratory. The WHO-UNEP
2012 report also does not address the fact that most EDCs have
much lower potency than endogenous hormones and potency is
important regardless of the life stage at which exposure occurs. Fi-
nally, consideration of low dose effects and NMDRs do not exclude
the need to consider potency and exposure.
It is also important to emphasize that the Summary for Decision-
Makers, while implied by the title to be a synopsis of the main re-
port, it is not truly representative of the main report. In many
cases, the Summary for Decision-Makers compounds the limitations
of the main report by making statements without supporting refer-
ences and providing more deﬁnitive conclusions. Consequently,
this companion report cannot be considered a Summary nor
should it be relied onto make decisions regarding the regulation
of endocrine disruptors.
Overall, the WHO-UNEP 2012 report on endocrine disruptors
fails to achieve its objectives as an updated state-of-the-science re-
view on endocrine disrupting chemicals, and therefore, should not
be used to support evidence-based decisions. The scientiﬁc litera-
ture on endocrine disruption is voluminous, complex, heavily
nuanced and covers multiple disciplines, and has certainly ex-
panded greatly since theWHO-IPCS 2002 report – thus, warranting
a true update of the state of the science. Science and policy deci-
sions should not rely on professional opinion alone; rather, efforts
to advance our understanding of the potential impacts of endo-
crine disrupting chemicals on human health and wildlife need to
be based on objective and systematic reviews that transparently
capture the best available science and rely on explicit criteria for
the evaluation of the evidence. Therefore, a balanced and objective
review of all of the available literature with clearly stated objec-
tives and limitations is essential. Moreover, any updated review
of the literature must acknowledge controversies regarding the is-
sues, identify data gaps, and provide clear statements of conclu-
sions that are supported by the data. Only through such an
approach can all parties, regardless of position on the issues, be
conﬁdent in evidence-based decisions that arise from such a
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